While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

An open letter signed by more than 50 industry executives blasts a “fundamentally, fatally flawed” report that urges greater ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma ...

As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, ...

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...